MSH2 and fragile X syndrome: To test if MSH2 might have a similar effect on specific CpG residues in FXS ESCs, we performed bisulfite sequencing to look at the methylation status of 37 individual CpG sites in the FMR1 promoter region from − 394 to − 93 bp upstream of the CGG repeat.